


Synthesis of 2-Thio- and 2-Oxoimidazoles via Cascade Addition–Cycloisomerization Reactions of Propargylcyanamides

Robert L. Giles, Richard A. Nkansah, and Ryan E. Looper*

Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112

r.looper@utah.edu

Received October 30, 2009



A methodology to generate 2-thio- and 2-oxoimidazoles through an addition–cyclization–isomerization reaction of propargylcyanamides with thiol and alcohol nucleophiles is described. In general, the reaction sequence allows for the rapid formation of highly substituted 2-thio- and 2-oxoimidazoles in good to excellent yields.

Both 2-thio- and 2-oxoimidazoles represent medicinally important heterocyclic scaffolds. These target substructures are central to compounds possessing inhibitory activity against HIV-1 reverse transcriptase,¹ p38 MAP kinase,² as well as histamine-H3 antagonists³ (Figure 1). They have also been documented as key pharmacophores in agents for the treatment of thrombosis,⁴ inflammation, and asthma.⁵ The preparation of these heterocycles is usually accomplished by nucleophilic substitution of activated 2-sulfonyl-,⁶ 2-nitro-,⁷ or 2-haloimidazoles⁸ or by the alkylation of imidazolethiones.⁹ The substitution approach is often lengthy requiring multiple protecting group and oxidation manipulations, while alkylation is generally restricted to sp³ hybri-





FIGURE 1. Medicinally relevant 2-thio- and 2-oxoimidazoles.

dized electrophiles and can give mixtures of S/O and N alkylated products.

Our interest in the chemistry and biology of 2-aminoimidazoles¹⁰ prompted us to develop a one-pot addition–hydroamination–isomerization sequence to access these related heterocycles.¹¹ This approach generates highly substituted 2-aminoimidazoles in just three steps by the addition of secondary amines to propargylcyanamides, as shown in Scheme 1. This reaction required the addition of a metal catalyst and it was eventually found that La(III) promotes the reaction effectively.

SCHEME 1. Addition–Hydroamination–Isomerization Sequence



We felt that the success of this methodology might be expanded to incorporate the addition of sulfur and oxygen nucleophiles to propargylcyanamides to rapidly synthesize 2-thio- and 2-oxoimidazoles.¹² This approach would obviate the need to prepare an activated imidazole for nucleophilic substitution. It would also allow for S/O building blocks to be introduced as nucleophiles, thus complementing imidazolethione alkylation. In particular it would broaden substituent diversity with the inclusion of an S/O substituent bearing an adjacent sp² hybridized carbon atom.

One of the key aspects to this chemistry is the rapid preparation of the propargylcyanamide precursors (Table 1). The propargylcyanamides (**2a–d**) used in this study were prepared in two steps by a iminium–acetylide three-component coupling (3-CC) to give the propargylamines **1a–d**.¹³ Cleavage of the tertiary amine with cyanogen bromide gave the propargylcyanamides **2a–d** with cleavage of the

(1) (a) Loksha, Y. M.; El-Barbary, A. A.; El-Baadawi, M. A.; Nielsen, C.; Pedersen, E. B. *Bioorg. Med. Chem.* **2005**, *13*, 4209. (b) Loksha, Y. M.; El-Baadawi, M. A.; El-Barbary, A. A.; Pedersen, E. B.; Nielsen, C. *Arch. Pharm. Pharm. Med. Chem.* **2003**, *336*, 175.

(2) Laufer, S. A.; Hauser, D. R. J.; Domeyer, D. M.; Kinkel, K.; Liedtke, A. J. *J. Med. Chem.* **2008**, *51*, 4122.

(3) Jablonowski, J. A.; Ly, K. S.; Bogenstaetter, M.; Dvorak, C. A.; Boggs, J. D.; Dvorak, L. K.; Lord, B.; Miller, K. L.; Mazur, C.; Wilson, S. J.; Lovenberg, T. W.; Carruthers, N. I. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 203.

(4) Nishi, T.; Uno, T.; Koga, Y.; Chu, G. N. Patent EP 240015, **1987**.

(5) Fenske, D. C.; Kuo, E. A.; Tully, W. R. U.S. Patent 4,810,828, **1989**.

(6) Jarosinski, M. A.; Anderson, W. K. *J. Org. Chem.* **1991**, *56*, 4058.

(7) Goldmann, P.; Wuest, J. D. *J. Am. Chem. Soc.* **1981**, *103*, 6224.

(8) Heras, M.; Ventura, M.; Linden, A.; Villalgorido, J. M. *Synthesis* **1999**, 1613.

(9) For representative examples see: (a) Tweit, R. C.; Kreider, E. M.; Muir, R. D. *J. Med. Chem.* **1973**, *16*, 1161. (b) Anderson, W. K.; Bhattacharjee, D.; Houston, D. M. *J. Med. Chem.* **1989**, *32*, 119. (c) Theoclitou, M.-E.; Delaet, N. G. J.; Robinson, L. A. *J. Comb. Chem.* **2002**, *4*, 315.

(10) Sullivan, J. D.; Giles, R. L.; Looper, R. E. *Curr. Bioact. Compd.* **2009**, *5*, 39.

(11) Giles, R. L.; Sullivan, J. D.; Steiner, A. M.; Looper, R. E. *Angew. Chem., Int. Ed.* **2009**, *48*, 3116.

(12) A conceptually related sequence has been reported for the addition of H₂S to allenylthiouras to generate imidazolethiones: Devan, B.; Rajagopalan, K. *Tetrahedron Lett.* **1994**, *35*, 1585.

(13) (a) Koradin, C.; Polborn, K.; Knochel, P. *Angew. Chem., Int. Ed.* **2002**, *41*, 2535. (b) Gommermann, N.; Koradin, C.; Polborn, K.; Knochel, P. *Angew. Chem., Int. Ed.* **2003**, *42*, 5763. (c) Aschwanden, P.; Stephenson, C. R. J.; Carreira, E. M. *Org. Lett.* **2006**, *8*, 2437.

TABLE 1. Synthesis of Propargylcyanamides

Coupling Partners	3° Amine	Cyanamide
$\text{Ar}-\text{N}(\text{R}^1)-\text{H}$ $\text{R}^3-\text{C}\equiv\text{C}-\text{R}^2-\text{CHO}$	$\text{R}^1-\text{N}(\text{Ar})-\text{R}^2-\text{C}\equiv\text{C}-\text{R}^3$	$\text{R}^1-\text{N}(\text{C}\equiv\text{N})-\text{R}^2-\text{C}\equiv\text{C}-\text{R}^3$
CuBr (10 mol %) PhMe or MeCN	BrCN, K ₂ CO ₃ dioxane, r.t.	
Coupling Partners PMB ₂ NH PMP \equiv HCHO	PMB-N(PMB)-C≡C-PMP 1a , 98%	PMB-N(C≡N)-C≡C-PMP 2a , 94%
PMBNHBn Ph \equiv HCHO	Bn-N(PMB)-C≡C-Ph 1b , 90%	Bn-N(C≡N)-C≡C-Ph 2b , 90%
PMBNMe Ph \equiv PhCH ₂ CHO	Me-N(PMB)-C≡C-Ph 1c , 94%	Me-N(C≡N)-C≡C-Ph 2c , 87%
PMBNMe PMP \equiv 4-BnOPhCH ₂ CHO	Me-N(PMB)-C≡C-PMP 1d , 98%	Me-N(C≡N)-C≡C-PMP 2d , 76%

intermediate cyanoammonium salt at the activated benzylic position of the PMB group.¹⁴

We initially investigated the addition–cyclization–isomerization sequence. While we observed formation of **3a** after heating a solution of the propargylcyanamide **2a** with ethanethiol, only ~5% of the propargylcyanamide had been converted to the desired 2-thioimidazole after 24 h at 150 °C. The poor electrophilic nature of *N,N*-dialkylcyanamides suggested that a Lewis acid catalyst or an anionic species would be required to effect addition to the cyanamide.^{15,16} In contrast to the addition of amines to propargylcyanamides, La(III) did not catalyze product formation.¹¹ This was worrisome as we had previously noted that the propargylcyanamides undergo isomerization to the allenecyanamides under basic conditions, resulting in decomposition/polymerization. Thus it was questionable if thiolate anions ($\text{p}K_{\text{a}} \approx 8\text{--}11$)¹⁷ would be capable of isomerizing the propargylcyanamides. Fortunately, the addition of 5 equiv of Hunig's base in the reaction mixture led to complete consumption of the propargylcyanamide after only 12 h at 120 °C to give 2-ethylthioimidazole **3a** in 67% yield (Table 2, entry 1). Treatment of the other cyanamides under the same conditions gave comparative results (entries 2–4). Benzylic thiols also gave the 2-thioimidazoles in moderate to good yields (Table 2, entries 5–8). Thiophenols are also competent partners in this reaction sequence (Table 2, entries 9–12) and react chemoselectively in the presence of phenols (Table 2, entries 13–16).

For experimental convenience we were using an excess of thiol in the addition–cyclization–isomerization sequence;

TABLE 2. Scheme 2 Synthesis of 2-Thioimidazoles

Entry	cyanamide	thiol	2-thioimidazole	Yield
			$\text{R}_1-\text{N}(\text{R}_2)-\text{C}\equiv\text{C}-\text{R}_3$ $\xrightarrow[\text{120}^\circ\text{C, 12-24 h}]{\text{thiol (3-10 equiv.)}, \text{iPr}_2\text{NEt (5-15 equiv.)}, \text{iPrOH (0.25 M)}}$ $\text{R}_1-\text{N}(\text{R}_2)-\text{C}(\text{R}_3)=\text{N}-\text{S}-\text{R}_4$ 2a-d → 3-6	
1	2a	MeSH	3a	67%
2	2b	MeSH	3b	77%
3	2c	MeSH	3c	93%
4	2d	MeSH	3d	82%
5	2a	MeO-C ₆ H ₄ -CH ₂ -SH	4a	82%
6	2b	MeO-C ₆ H ₄ -CH ₂ -SH	4b	71%
7	2c	MeO-C ₆ H ₄ -CH ₂ -SH	4c	97%
8	2d	MeO-C ₆ H ₄ -CH ₂ -SH	4d	53%
9	2a	Ph-SH	5a	83%
10	2b	Ph-SH	5b	91%
11	2c	Ph-SH	5c	94%
12	2d	Ph-SH	5d	87%
13	2a	HO-C ₆ H ₄ -CH ₂ -SH	6a	74%
14	2b	HO-C ₆ H ₄ -CH ₂ -SH	6b	64%
15	2c	HO-C ₆ H ₄ -CH ₂ -SH	6c	77%
16	2d	HO-C ₆ H ₄ -CH ₂ -SH	6d	78%

however, we found that the use of dithiols in the presence of 1.5 equiv of cyanamide per thiol was capable of producing bis-2-thioimidazoles **7a** and **7b** in good yields (Scheme 2).

Since we had noted that isopropanol was a noncompetitive solvent for the La(III) catalyzed addition of amines to cyanamides, it was not surprising to observe that they were not competent nucleophiles in the addition–cycloisomerization sequence under neutral conditions.¹¹ Also, we had previously observed that sterically hindered alkoxides (KO^tBu in THF) quantitatively isomerized propargylcyanamides to the allenecyanamides in ~10 min at 0 °C. Due to the increased basicity of alkoxides relative to thiolates, which could favor isomerization over addition to the cyanamide, we were pessimistic that phenoxides or alkoxides

(14) von Braun, J. *Chem. Ber.* **1900**, 33, 1438.


(15) Snider, B. B.; O'Hare, S. M. *Tetrahedron Lett.* **2001**, 42, 2455.

(16) Dalby, K. N.; Jencks, W. P. *J. Chem. Soc., Perkin Trans. 2* **1997**, 1555.

(17) (a) Pascal, I.; Tarbell, D. S. *J. Am. Chem. Soc.* **1957**, 79, 6015.

(b) Kreevoy, M. M.; Harper, E. T.; Duvall, R. E.; Wilgus, H. S. III; Ditsch, L. T. *J. Am. Chem. Soc.* **1960**, 82, 4899.

SCHEME 2. Synthesis of Bis-2-thioimidazoles



would be competent nucleophiles in this chemistry. Contrary to our assumptions, treatment of cyanamide **2a** with phenol in the presence of K₂CO₃ successfully delivered the 2-phenoxyimidazole (**8a**) in 77% yield (Table 3, entry 1). Toluene proved to be the best solvent for temperature considerations.

TABLE 3. Synthesis of 2-Oxoimidazoles

Entry	cyanamide	conditions ^a	alcohol	2-oxoimidazole	Yield
1	2a	A		8a	77%
2	2c	A		8b	76%
3	2d	A	HO-C ₆ H ₅	8c	62%
4	2c	B	MeOH	8d	72%
5	2c	C			82%
6	2c	C	iPrOH	8e	67%

We then pressed our nucleophile choice to alkoxides and were quite surprised to see that MeOH and Huning's base gave the methoxyimidazole **8d** in 72% yield (Table 3, entry 4). The use of K₂CO₃ worked equally as well to promote the reaction (entry 5). We were quite surprised to see that iPrOH, the solvent choice for the La(III) catalyzed amine addition–hydroamination–isomerization manifold, delivered the 2-isopropoxyimidazole **8e** in 67% yield with the addition of K₂CO₃ (entry 6).

In conclusion we have developed optimal conditions for the addition of both alkyl and aryl thiols and alcohols to propargylcyanamides. Subsequent cycloisomerization delivers the 2-thio- or 2-oxoimidazoles in good yields. The fact that equimolar KOtBu decomposes the substrates but catalytically generated nucleophiles (e.g., K₂CO₃/iPrOH) are competent partners suggests that thio- or oxo-nucleophiles with a pK_a < ~18 should be tolerated under these conditions. Interestingly La(III) does not influence the reaction of thio- or oxo-nucleophiles with propargylcyanamides, suggesting a unique catalytic role for La(III) in the addition–hydroamination–isomerization sequence with amines.

Studies to elucidate this mechanistic difference are currently underway and will be reported in due course.

Experimental Section

Typical Procedure for the Preparation of Propargylamines. *N,N*-Bis(4-methoxybenzyl)-3-(4-methoxyphenyl)prop-2-yn-1-amine (**1a**). To a 100 mL round-bottomed flask containing a magnetic stir bar was added bis(4-methoxybenzyl)amine (PMB₂NH) (3.73 g, 14.5 mmol, 1.0 equiv), 37% aqueous solution of formaldehyde (6.54 g, 6.00 mL, 80.6 mmol, 5.6 equiv), 4-methoxyphenyl acetylene (2.02 g, 15.3 mmol, 1.06 equiv), CuBr (0.209 g, 1.45 mmol, 0.1 equiv), and MeCN (45 mL). The reaction mixture was allowed to stir at room temperature for 24 h. The reaction mixture was filtered through a plug of Celite before the solvent was removed under reduced pressure. Purification of the material was accomplished by flash column chromatography on a 5.7 × 15 cm column, eluting with 20% ethyl acetate/hexanes. The product containing fractions were combined and then concentrated under reduced pressure to give propargylamine **1a** (5.77 g, 98% yield) as a light yellow oil. *R*_f 0.49 (35% ethyl acetate/hexanes). ¹H NMR (CDCl₃, 500 MHz): δ 7.45 (ddd, *J* = 9.5, 2.5, 2.0 Hz 2H), 7.35 (ddd, *J* = 8.4, 2.9, 1.8 Hz 4H), 6.90–6.86 (m, 6H), 3.81 (s, 6H), 3.83 (s, 3H), 3.80 (s, 6H), 3.67 (s, 2H), 3.43 (s, 2H). ¹³C NMR (CDCl₃, 125 MHz): δ 159.6, 159.0, 133.4, 131.3, 130.5, 115.8, 114.2, 113.9, 85.8, 83.2, 57.1, 55.6, 55.5, 42.0. ¹³C DEPT NMR (CDCl₃, 125 MHz): δ CH₃: (2 × 55.4); CH₂: 57.0, 41.8; CH: 133.3, 132.3, 131.1, 114.0, 113.8; CH₀: 158.9, 85.8, 83.2. IR (neat): 2933, 2834, 1607, 1509, 1463, 1291, 1246, 1172, 1106, 1034, 832, 668 cm⁻¹. HRMS (ESI) calcd for C₂₆H₂₈NO₃ *m/z* (M + H) 402.2069, obsd 402.2055.

Typical Procedure for the Preparation of Propargylcyanamides. *N*-(4-Methoxybenzyl)-*N*-(3-(4-methoxyphenyl)prop-2-yn-1-yl)cyanamide (**2a**). To a 250 mL round-bottomed flask containing a magnetic stir bar was added propargylamine **1a** (5.030 g, 12.5 mmol, 1.0 equiv), 3 M solution of CNBr in CH₂Cl₂ (8.40 mL, 25.1 mmol, 2.0 equiv), K₂CO₃ (3.916 g, 28.33 mmol, 2.3 equiv), and dioxane (125 mL). The reaction mixture was allowed to stir at rt for 24 h before being quenched with a saturated aqueous solution of NaHCO₃ (25 mL). The reaction mixture was diluted in CH₂Cl₂ (100 mL) and water (50 mL) and the layers were separated. The aqueous phase was extracted with CH₂Cl₂ (2 × 25 mL). The organic extract was then dried over Na₂SO₄, filtered, and concentrated under reduced pressure. Purification of the material was accomplished by flash column chromatography on a 5.7 × 15 cm column, eluting with 20% ethyl acetate/hexanes. The product containing fractions were combined and then concentrated under reduced pressure to give cyanamide **2a** (3.608 g, 94% yield) as a light yellow oil. *R*_f 0.40 (35% ethyl acetate/hexanes). ¹H NMR (CDCl₃, 500 MHz): δ 7.40 (d, *J* = 9.0 Hz, 2H), 7.31 (d, *J* = 9.0 Hz, 2H), 6.91 (d, *J* = 9.0 Hz, 2H), 6.85 (d, *J* = 9.0 Hz, 2H), 4.26 (s, 2H), 3.92 (s, 2H), 3.81 (s, 3H), 3.80 (s, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ 160.3, 160.2, 133.6, 130.7, 126.0, 117.7, 114.5, 114.4, 114.3, 114.2, 87.2, 80.1, 55.6, 55.5, 54.3, 41.1. ¹³C DEPT NMR (CDCl₃, 125 MHz): δ CH₃: 55.6, 55.5; CH₂: 54.3, 41.1; CH: 133.6, 130.7, 114.5, 114.3; CH₀: 160.3, 160.2, 126.0, 117.7, 114.5, 114.4, 87.2, 80.1. IR (neat): 2931, 2836, 1721, 1643, 1612, 1585, 1512, 1491, 1453, 1407, 1359, 1302, 1247, 1223, 1175, 1145, 1107, 1078, 1034, 905, 822, 758, 696 cm⁻¹. HRMS (ESI) calcd for *m/z* C₁₉H₁₈N₂NaO₂ (M + Na) 329.1266, obsd 329.1263.

Typical Procedure for the Preparation of 2-Thioimidazoles. **Preparation of 2-(Ethylthio)-1,4-bis(4-methoxybenzyl)-1H-imidazole (3a).** To a 15 mL high-pressure tube containing a magnetic stir bar was added cyanamide **2a** (0.107 g, 0.347 mmol, 1.0 equiv), ethanethiol (0.216 g, 260 μL, 3.47 mmol, 10.0 equiv), *N,N*-diisopropylethylamine (0.674 g, 910 μL, 5.21 mmol, 15.0 equiv), and isopropanol (2 mL). The high-pressure tube was then sealed and placed in a preheated 120 °C oil bath. After 24 h

at 120 °C, the high pressure was removed from the oil bath, which was then left to cool to rt. The crude reaction mixture was diluted in CH₂Cl₂ (50 mL) and water (50 mL) and the layers separated. The aqueous phase was extracted with CH₂Cl₂ (2 × 25 mL). The organic extract was then dried over Na₂SO₄, filtered, and concentrated under reduced pressure. Purification of the material was accomplished by flash column chromatography on a 2.5 × 15 cm column, eluting with 35% ethyl acetate/hexanes (w/3% triethylamine). The product containing fractions were combined and then concentrated under reduced pressure to give 2-thioimidazole **3a** (0.086 g, 67% yield) as a light yellow oil. *R_f* 0.24 (35% ethyl acetate/hexanes). ¹H NMR (CDCl₃, 500 MHz): δ 7.13 (d, *J* = 8.8 Hz, 2H), 7.01 (d, *J* = 8.8 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 6.77 (d, *J* = 8.8 Hz, 2H), 6.42 (s, 1H), 4.96 (s, 2H), 3.80 (s, 2H), 3.73 (s, 6H), 2.94 (q, *J* = 7.6 Hz, 2H), 1.23 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz): δ 159.3, 158.0, 143.5, 140.5, 132.2, 130.0, 128.9, 128.7, 118.3, 114.3, 113.8 (2 × 55.4), 49.7, 34.4, 29.5, 15.7. DEPT ¹³C NMR (CDCl₃, 125 MHz): δ CH₃: (2 × 55.4), 15.7; CH₂: 49.7, 34.4, 29.5; CH: 130.0, 128.7, 118.3, 114.3, 113.8; CH₀: 159.3, 158.0, 143.5, 140.5, 132.2, 128.9. IR (neat): 2931, 2834, 1612, 1584, 1512, 1453, 1300, 1247, 1176, 1106, 1034, 794 cm⁻¹. HRMS (ESI) calcd for C₂₁H₂₄N₂O₂S *m/z* (M + H) 369.1637, obsd 369.1641.

Typical Procedure for the Preparation of 2-Oxoimidazoles. 1,4-Bis(4-methoxybenzyl)-2-phenoxy-1*H*-imidazole (8a**).** In a 15 mL high-pressure tube containing a magnetic stir bar was added cyanamide **2a** (0.120 g, 0.392 mmol, 1.0 equiv), phenol (0.111 g, 0.118 mmol, 3.0 equiv), K₂CO₃ (0.271 g, 1.96 mmol, 5.0 equiv), and toluene (1.5 mL). The high-pressure tube was then sealed and placed in a preheated 150 °C oil bath. After 24 h at 150 °C, the high pressure was removed from the oil bath, which was then left to cool to rt. The crude reaction mixture was diluted in CH₂Cl₂ (50 mL) and water (50 mL) and the layers

separated. The aqueous phase was extracted with CH₂Cl₂ (2 × 25 mL). The organic extract was then dried over Na₂SO₄, filtered, and concentrated under reduced pressure. Purification of the material was accomplished by flash column chromatography on a 2.5 × 15 cm column, eluting with 35% ethyl acetate/hexanes (w/1% triethylamine). The product containing fractions were combined and then concentrated under reduced pressure to give 2-oxoimidazole **8a** (0.121 g, 77% yield) as a light yellow oil. *R_f* 0.43 (40% ethyl acetate/hexane w/1% triethylamine). ¹H NMR (CDCl₃, 500 MHz): δ 7.32 (dd, *J* = 7.3, 8.8 Hz, 2H), 7.20–7.14 (m, 4H), 7.13–7.07 (m, 3H), 6.84–6.81 (m, 4H), 6.13 (s, 1H), 4.82 (s, 2H), 3.77 (s, 3H), 3.77 (s, 3H), 3.76 (s, 2H). ¹³C NMR (CDCl₃, 125 MHz): δ 159.4, 158.1, 155.7, 148.8, 137.9, 132.1, 130.1, 129.8, 129.1, 128.7, 124.1, 118.1, 114.3, 113.9, 112.3, 55.4, 55.4, 47.8, 34.7. ¹³C DEPT NMR (CDCl₃, 125 MHz): δ CH₃: 55.4, 55.4; CH₂: 47.8, 34.7; CH: 130.1, 129.8, 129.1, 124.1, 118.1, 114.3, 113.9, 112.3. IR (neat): 2933, 2834, 1611, 1587, 1509, 1476, 1299, 1240, 1204, 1174, 1030, 807, 755, 687 cm⁻¹. HRMS (ESI) calcd for C₂₅H₂₅N₂O₃ *m/z* (M + H) 401.1865, obsd 401.1860.

Acknowledgment. We are grateful to the Donors of the American Chemical Society Petroleum Research Fund for partial support of this research. We are also grateful for financial support from the University of Utah Research foundation. We thank Mr. John Sullivan for the preparation of substrate **2a**.

Supporting Information Available: Experimental details and ¹H, ¹³C, and ¹³C DEPT NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.